Literature DB >> 16985801

Validity of the "bother score" in the evaluation and treatment of symptomatic benign prostatic hyperplasia.

Michael P O'leary.   

Abstract

Benign prostatic hyperplasia (BPH) is a condition that is common among older men. It causes a variety of clinically significant lower urinary tract signs and symptoms. BPH is rarely life-threatening; the decision to seek treatment is frequently based on the degree to which patients find the symptoms bothersome and disruptive of daily activities. Recently developed reliable and valid outcome measures to evaluate treatments for BPH are clinical tools that urologists can use to determine the extent of bother and make treatment decisions. A single question used to determine the "bother score" provides a widely used and statistically valid measure of the need for treatment of BPH. Validation data support the argument that the bother score is a statistically reliable measure of treatment outcome in patients with BPH who view their symptoms as bothersome.

Entities:  

Year:  2005        PMID: 16985801      PMCID: PMC1477553     

Source DB:  PubMed          Journal:  Rev Urol        ISSN: 1523-6161


  31 in total

Review 1.  Impact of drug therapy on benign prostatic hyperplasia-specific quality of life.

Authors:  P R Rhodes; R H Krogh; R C Bruskewitz
Journal:  Urology       Date:  1999-06       Impact factor: 2.649

2.  Prostate-specific antigen (PSA) best practice policy. American Urological Association (AUA).

Authors: 
Journal:  Oncology (Williston Park)       Date:  2000-02       Impact factor: 2.990

3.  One-year follow-up of 2829 patients with moderate to severe lower urinary tract symptoms treated with alfuzosin in general practice according to IPSS and a health-related quality-of-life questionnaire. BPM Group in General Practice.

Authors:  B Lukacs; J C Grange; D Comet
Journal:  Urology       Date:  2000-04       Impact factor: 2.649

Review 4.  Quality-of-life assessment in patients with benign prostatic hyperplasia: effects of various interventions.

Authors:  J E Batista-Miranda; M D Diez; P A Bertrán; H Villavicencio
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

5.  Benign prostatic hyperplasia. Patient evaluation and relief of obstructive symptoms.

Authors:  R D Chow
Journal:  Geriatrics       Date:  2001-03

6.  Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group.

Authors:  P van Kerrebroeck; A Jardin; K U Laval; P van Cangh
Journal:  Eur Urol       Date:  2000-03       Impact factor: 20.096

Review 7.  LUTS, ED, QOL: alphabet soup or real concerns to aging men?

Authors:  M P O'Leary
Journal:  Urology       Date:  2000-11-01       Impact factor: 2.649

8.  A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia.

Authors:  R S Kirby; M Andersen; P Gratzke; C Dahlstrand; K Høye
Journal:  BJU Int       Date:  2001-02       Impact factor: 5.588

9.  Sexual dysfunction in men with lower urinary tract symptoms.

Authors:  S J Frankel; J L Donovan; T I Peters; P Abrams; N F Dabhoiwala; D Osawa; A T Lin
Journal:  J Clin Epidemiol       Date:  1998-08       Impact factor: 6.437

10.  Doxazosin added to single-drug therapy in hypertensive patients with benign prostatic hypertrophy.

Authors:  N Martell; M Luque
Journal:  J Clin Hypertens (Greenwich)       Date:  2001 Jul-Aug       Impact factor: 3.738

View more
  9 in total

1.  Physiologic reactivity to a laboratory stress task among men with benign prostatic hyperplasia.

Authors:  Philip M Ullrich; Susan K Lutgendorf; Karl J Kreder
Journal:  Urology       Date:  2007-09       Impact factor: 2.649

2.  Lack of Patient-Clinician Concordance in Cancer Patients: Its Relation With Patient Variables.

Authors:  Kavita D Chandwani; Fengmin Zhao; Gary R Morrow; Teresa L Deshields; Lori M Minasian; Judith Manola; Michael J Fisch
Journal:  J Pain Symptom Manage       Date:  2017-02-06       Impact factor: 3.612

3.  Treatment satisfaction after 1 year high-power potassium-titanyl-phosphate photoselective vaporization of the prostate.

Authors:  Ja Hyeon Ku; Min Chul Cho; Hyeong Seok Kim; Jae-Seung Paick; Soo Woong Kim
Journal:  Asian J Androl       Date:  2010-05-24       Impact factor: 3.285

4.  IPSS "bother question" score predicts health-related quality of life better than total IPSS score.

Authors:  Florin V Hopland-Nechita; John R Andersen; Christian Beisland
Journal:  World J Urol       Date:  2022-01-09       Impact factor: 4.226

5.  Nocturia and overnight polysomnography in Parkinson disease.

Authors:  Camille P Vaughan; Jorge L Juncos; Lynn Marie Trotti; Theodore M Johnson; Donald L Bliwise
Journal:  Neurourol Urodyn       Date:  2013-01-28       Impact factor: 2.696

6.  The value of appropriate assessment prior to specialist referral in men with prostatic symptoms.

Authors:  M R Quinlan; B J O'Daly; M F O'Brien; S Gardner; G Lennon; D W Mulvin; D M Quinlan
Journal:  Ir J Med Sci       Date:  2009-04-15       Impact factor: 1.568

7.  Assessing health-related quality of life in urology - a survey of 4500 German urologists.

Authors:  A Schmick; M Juergensen; V Rohde; A Katalinic; A Waldmann
Journal:  BMC Urol       Date:  2017-06-19       Impact factor: 2.264

8.  Integrated Item Response Theory Modeling of Multiple Patient-Reported Outcomes Assessing Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia.

Authors:  Yassine Kamal Lyauk; Trine Meldgaard Lund; Andrew C Hooker; Mats O Karlsson; Daniël M Jonker
Journal:  AAPS J       Date:  2020-07-29       Impact factor: 4.009

9.  Bounded Integer Modeling of Symptom Scales Specific to Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.

Authors:  Yassine Kamal Lyauk; Daniël M Jonker; Andrew C Hooker; Trine Meldgaard Lund; Mats O Karlsson
Journal:  AAPS J       Date:  2021-02-25       Impact factor: 4.009

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.